psychiatryRounds

Connecting Psychiatry - Expert community for all mental health professionals

(PSYCHIATRIC TIMES) - Attention-deficit/hyperactivity disorder (ADHD) is most commonly identified and studied in school-aged children (6- to 12-year-olds). It is, however, a syndrome that occurs across the life cycle-preschool-aged children, adolescents and adults also suffer from ADHD. Since ADHD is associated with significant psychosocial dysfunction and often associated with poor outcomes, safe and effective treatments are needed to treat people of all ages with this condition.

Clear evidence from a sizable number of published short-term studies (and a relatively few long-term trials) indicates that the psychostimulants methylphenidate (Ritalin, Concerta, Methylin, Metadate); dextroamphetamine (Dexedrine); and the mixed amphetamine salt preparation Adderall all have efficacy in treating school-aged children with ADHD. The most extensively studied of these agents by far is methylphenidate (Wilens and Spencer, 2000).

In the past, weight-based dosing strategies for treating school-aged children with psychostimulants have been suggested (Findling and Dogin, 1998). However, recent evidence supports the assertion that this approach might not be optimal (Findling et al., 2001; Rapport and Denney, 1997). For this reason, when patients with ADHD start stimulant therapy, it is now generally recommended that medication be initiated at a relatively low dose and gradually titrated upward in order to maximize the salutary effects and minimize the adverse events of these drugs. For school-aged children, maximum recommended daily doses of methylphenidate are approximately 60 mg per day. For amphetamine-based preparations, about 40 mg is the maximum dose recommended each day (Greenhill et al., 2002).

Despite the fact that the overwhelming amount of research on ADHD has focused on school-aged children, there is evidence that suggests younger, preschool-aged children as well as older adolescents may also benefit from psychostimulant treatment. Unfortunately, very little data are available to guide treatment with psychostimulants in these cohorts.

Very few methodologically rigorous studies have examined the use of psychostimulants in preschool-aged children with ADHD. What data do exist suggest that psychostimulants may be useful for this group, but that these youngest of patients may have higher rates of side effects (particularly those related to mood) than older patients (Firestone et al., 1998; Greenhill, 1998). Despite the relatively recent appreciation regarding the limitations of weight-based dosing for psychostimulants in children with ADHD, most of the studies of psychostimulants in preschool-aged children have employed weight-based dosing strategies in their study designs. Given that flexible dosing strategies were not employed, the question remains whether or not preschoolers benefit from doses of methylphenidate similar to those of older children.

Not unlike the preschool population, only a handful (less than 10) of published double-blind, placebo-controlled studies have examined the use of psychostimulants in adolescents. Almost all of these trials were short-term and focused on the use of methylphenidate. The available evidence suggests that the psychostimulants have efficacy in treating adolescents with ADHD. Furthermore, these agents appear to be as effective in teen-agers as they are in younger children (Findling et al., 2001). In most adolescent ADHD trials, weight-based psychostimulant dosing strategies that tested doses similar to those used in younger children (0.15 mg/kg to 0.50 mg/kg) were employed.

To summarize, albeit few studies have examined the use of psychostimulants in preschool-aged children and teen-agers, they are consistent in their finding that these agents have short-term efficacy in the treatment of ADHD. Most of these studies employed weight-based dosing strategies. This tactic is unfortunate because although weight-based dosing may be acceptable (but not ideal) in school-aged children, using similar milligram per kilogram doses may be particularly problematic in adolescents and younger children. Differences in drug biodisposition that may occur across the first two decades of life are at the root of such challenges. Given that drugs have shorter half-lives in younger children than they do in older youths, smaller weight-adjusted doses for medication may be optimal for adolescent patients when they are compared to those doses that are optimal for younger children (Clein and Riddle, 1995). Unfortunately, until recently, few studies have carefully examined whether or not differences in weight-adjusted dosing of psychostimulants occur between these three age groups.

For full article, please visit:
http://www.psychiatrictimes.com/adhd/article/10168/47926

Views: 5

Comment

You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds


psychiatryRounds Social Media

Sponsors

CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2019   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service